Todd A. Verdoorn

NeuroTherapeutics Pharma, Inc. is a biopharmaceutical company focused on developing therapies for diseases associated with central nervous system hyper-excitability. It is developing compounds that decrease or eliminate aberrant excitatory discharges by working through a new mechanism of action. The firm's proprietary molecules target a novel molecular site that will create a pipeline of potential new treatments for multiple CNS disorders. The company's lead compound, NTP-2014, has exhibited excellent efficacy results in multiple preclinical models of epilepsy, acute and neuropathic pain. NeuroTherapeutics Pharma was founded in 2006 and is headquartered in Chicago, IL.

Orasi Medical, Inc. is a privately held, early stage medical device company engaged in the development and commercialization of technology to diagnose and monitor neurological diseases. They have developed a painless, non-invasive test that takes less than ten (10) minutes to administer and, based on the results of its current research, is more accurate than current clinical practice. Initially, its aim is to develop the first FDA cleared test for the diagnosis of Alzheimer's disease. In addition, they are developing products for pharmaceutical companies to measure treatment effect and reduce the cost of clinical drug trials for neurological diseases. Ultimately, its long-term goal is to set the standard of care for diagnosis and monitoring of major neurological diseases such as Alzheimer's disease, multiple sclerosis, Parkinson's, autism, depression and attention deficit hyperactivity disorder (ADHD).

Algos PreClinical Services, Inc. engages in preclinical pain drug development. It specializes in preclinical in vivo pain research and program consulting. The company was founded by Susanne C. Dvorak and Todd C. Verdoorn in 2003 and is headquartered in Roseville, MN.